FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 357 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... October 20, 2020 Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 Color-Blind Groom Sees Color For First Time After Bride Surprises Him... November 9, 2021 Load more HOT NEWS Survivorship and Immune Checkpoint Inhibitors EMA Recommends Extension of Therapeutic Indications for Atezolizumab Medicare Open Enrollment is Almost Here-What You Need to Know for... Updated Nutrition Facts Label Reflects Science on Diet and Health, including...
